1. Pharmacokinetics of Theophylline in Hepatic Disease
Antoinette Mangione, Pharm. D., Thomas E. Imhoff, Pharm. D., Richard V. Lee, M.D., Lin Yee Shum, B.Pharm, William J. Jusko, Ph.D. 
CHEST 
Volume 73, Issue 5, Pages (May 1978)
DOI: /chest
Copyright © 1978 The American College of Chest Physicians Terms and Conditions

2. Figure 1
Course of time for absorption and elimination of theophylline in serum (solid circles and solid lines) and saliva (open circles and broken lines) of two cirrhotic patients. Lines were fitted to data by computer; t½, half-life of theophylline.
CHEST  , DOI: ( /chest )
Copyright © 1978 The American College of Chest Physicians Terms and Conditions

3. Figure 2
Body clearance of theophylline in cirrhotic patients (proven by biopsy, solid circles; and not proven by biopsy, open circles), normal control subjects, and control patients. Horizontal lines depict means; vertical bars indicate ± 1 SD.
CHEST  , DOI: ( /chest )
Copyright © 1978 The American College of Chest Physicians Terms and Conditions

4. Figure 3
Half-life (in hours) for elimination of theophylline in cirrhotic patients (proven by biopsy, solid circles; and not proven by biopsy, open circles) and normal subjects. Horizontal lines indicate means; vertical bar indicates ± 1 SD.
CHEST  , DOI: ( /chest )
Copyright © 1978 The American College of Chest Physicians Terms and Conditions

5. Figure 4
Body clearances of theophylline in relation to logarithmic scale for serum concentrations of bilirubin (r = —0.79). Arrows depict mean body clearances for cirrhotic patients with bilirubin levels less than (upper arrow) or greater than (lower arrow) 1.5 mg/100 ml. Data are from this study (circles) and from Piafsky et al12 (squares).
CHEST  , DOI: ( /chest )
Copyright © 1978 The American College of Chest Physicians Terms and Conditions